The New Arthritis Breakthrough
The Arthritis Cure, Revised and Updated
John Hopkins
Genentech And Biogen Idec Announce Positive Results From A Phase 3 Trial Of Rituxan In Patients With Rheumatoid Arthritis Who Inadequately Responded
Mon, 28 Jan 2008 00:00:00 PST
Genentech, Inc. (NYSE: DNA) and Biogen Idec (Nasdaq: BIIB) announced that a Phase III clinical study of Rituxan® (rituximab) in biologic-naïve patients met its primary endpoint of a significantly greater proportion of Rituxan-treated patients achieving an American College of Rheumatology (ACR) 20 response at week 24, compared to placebo.
Arthritis In Dog
Arthritis Psoriatic Woman
The Arthritis Cure, Revised and Updated
John Hopkins
Genentech And Biogen Idec Announce Positive Results From A Phase 3 Trial Of Rituxan In Patients With Rheumatoid Arthritis Who Inadequately Responded
Mon, 28 Jan 2008 00:00:00 PST
Genentech, Inc. (NYSE: DNA) and Biogen Idec (Nasdaq: BIIB) announced that a Phase III clinical study of Rituxan® (rituximab) in biologic-naïve patients met its primary endpoint of a significantly greater proportion of Rituxan-treated patients achieving an American College of Rheumatology (ACR) 20 response at week 24, compared to placebo.
Arthritis In Dog
Arthritis Psoriatic Woman
Labels: Arthritis Psoriatic Woman
#social-bookmarks#posted by Ajax at
6:05 AM
0 Comments:
Post a Comment
<< Home